DEXTENZA®

DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg is approved for the treatment of pain following ophthalmic surgery. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.

For more information and full Prescribing Information, visit our new website at www.dextenza.com

INSERTION OF DEXTENZA


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma and intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

ADVERSE REACTIONS

The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (9%); intraocular pressure increased (5%); visual acuity reduced (2%); eye pain (1%); cystoid macular edema (1%); corneal edema (1%); and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see Full Prescribing Information.

DEXTENZA is dexamethasone delivered via hydrogel technology1,2

ACTIVATES1,2

  • With moisture
  • Swells to fit comfortably and securely in the canaliculus

RELEASES1,2

  • Dexamethasone for up to 30 days

RESORBS1,2

  • Slowly through the course of treatment
  • Clears via the nasolacrimal duct

1 DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2018.
2 Walters T et al. J Clin Exp Ophthalmol. 2016;7(4):1-11.
3 Durezol [package insert]. Fort Worth TX: Novartis; 2016.
4 Lotemax gel [package insert]. Bridgewater, NJ: Bausch & Lomb Inc; 2016